Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 570,119 | 681,101 | 392,588 | 414,619 | 393,949 |
| Marketable Securities | 17,363 | N/A | 58,949 | 95,233 | 442,891 |
| Receivables | 139,444 | 4,722 | 1,751 | 17,079 | 19,749 |
| Inventories | 26,753 | 0 | N/A | N/A | N/A |
| TOTAL | $797,749 | $720,692 | $477,593 | $548,853 | $888,858 |
| Non-Current Assets | |||||
| PPE Net | 5,366 | 7,011 | 11,816 | 14,569 | 30,066 |
| Investments And Advances | 79,972 | 143,747 | 0 | 0 | 0 |
| Intangibles | 28,077 | 23,926 | 26,319 | 28,712 | 44,934 |
| Other Non-Current Assets | 24,861 | 23,962 | 30,652 | 30,902 | 48,934 |
| TOTAL | $138,276 | $198,646 | $68,787 | $74,183 | $123,934 |
| Total Assets | $936,025 | $919,338 | $546,380 | $623,036 | $1,012,792 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 36,228 | 9,618 | 10,655 | 11,558 | 11,884 |
| Accrued Expenses | 118,139 | 92,601 | 122,965 | 98,039 | 87,965 |
| Other current liabilities | 120,222 | 33,071 | N/A | N/A | N/A |
| TOTAL | $287,971 | $154,400 | $143,844 | $121,428 | $135,069 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,852,470 | 1,721,382 | 1,726,729 | 1,707,615 | 1,703,805 |
| Deferred Revenues | 7,190 | 14,604 | 6,096 | 8,156 | N/A |
| Other Non-Current Liabilities | 866,522 | 491,800 | 25,142 | 40,797 | 64,835 |
| TOTAL | $2,724,065 | $2,222,692 | $1,745,549 | $1,744,943 | $1,744,725 |
| Total Liabilities | $3,012,036 | $2,377,092 | $1,889,393 | $1,866,371 | $1,879,794 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 193,863 | 190,189 | 175,832 | 151,373 | 147,608 |
| Common Shares | 202 | 196 | 181 | 157 | 154 |
| Retained earnings | -3,821,194 | -3,096,263 | -2,560,501 | -1,918,149 | -1,436,966 |
| Other shareholders' equity | 10,335 | 10,158 | 11,275 | 10,954 | 3,280 |
| TOTAL | $-2,076,011 | $-1,457,754 | $-1,343,013 | $-1,243,335 | $-867,002 |
| Total Liabilities And Equity | $936,025 | $919,338 | $546,380 | $623,036 | $1,012,792 |